Ligand Initiates Clinical Trial With The Selective Androgen Receptor Modulator LGD-4033, A Potential Treatment Of Muscle And Bone Disorders

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced the initiation of a Phase I clinical trial with LGD-4033, a next-generation selective androgen receptor modulator (SARM) designed to provide the benefits of androgen receptor stimulation on skeletal muscle and bone without the side effects of currently marketed androgens. The Phase I study will evaluate the safety, tolerability and pharmacokinetic profile of orally administered LGD-4033.

source : www.medicalnewstoday.com

Related News:

• European Medicines Agency Makes Recommendations To Minimise Risk Of…
• Breast Enhancement Surgeon on Long Island Nominated a "Best Of"
• $16 Million Grant From State Stem Cell Agency To Speed Research Of…
• Book and Media Reviews: American Psychiatric Publishing Textbook of…
• After Mastectomy: Making a Decision About Breast Reconstruction
• Robotic Surgery Expert Dr. David B. Samadi Discusses The Benefits Of…
• UM Doctor To Lead Clinical Trial For ALS
• Migraine as inspiration
• Impax Pharmaceuticals Reports Positive Results of Phase II Trial of…
• Analysis of TB treatment studies identifies gaps in guidelines